Pharmacokinetic study of Cc-292 in healthy subjects

Trial Profile

Pharmacokinetic study of Cc-292 in healthy subjects

Phase of Trial: Phase I

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Spebrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 25 Apr 2016 New trial record
    • 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top